This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Paratek Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Paratek Pharmaceuticals.

Wichtige Informationen

73.2%

Wachstumsrate der Gewinne

72.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	27.6%
Wachstumsrate der Einnahmen	13.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	07 Aug 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Apr 17

Paratek Pharmaceuticals: Patience Is Wearing Thin

Aug 24

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Aug 03

Could The Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Ownership Structure Tell Us Something Useful?

Feb 01

Paratek Pharmaceuticals secures $60M non-recourse loan for Hercules debt repayment

Jan 04

Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale

Dec 01

Paratek Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:PRTK - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	221	2	-9	N/A	2
12/31/2024	218	-14	30	N/A	3
12/31/2023	163	-46	-10	N/A	2
6/30/2023	177	-63	-23	-23	N/A
3/31/2023	167	-66	-36	-36	N/A
12/31/2022	160	-64	-66	-66	N/A
9/30/2022	117	-89	-66	-66	N/A
6/30/2022	111	-86	-27	-27	N/A
3/31/2022	139	-59	-46	-46	N/A
12/31/2021	130	-59	-49	-48	N/A
9/30/2021	114	-52	-53	-52	N/A
6/30/2021	104	-54	-108	-107	N/A
3/31/2021	55	-87	-95	-95	N/A
12/31/2020	47	-97	-104	-103	N/A
9/30/2020	40	-99	-116	-115	N/A
6/30/2020	30	-111	-115	-114	N/A
3/31/2020	23	-121	-129	-129	N/A
12/31/2019	17	-129	-134	-134	N/A
9/30/2019	25	-124	-118	-117	N/A
6/30/2019	21	-124	-110	-110	N/A
3/31/2019	19	-120	-98	-98	N/A
12/31/2018	17	-112	-81	-81	N/A
9/30/2018	5	-111	-85	-85	N/A
6/30/2018	5	-101	-80	-80	N/A
3/31/2018	13	-89	-73	-73	N/A
12/31/2017	13	-89	-80	-79	N/A
9/30/2017	8	-94	-82	-80	N/A
6/30/2017	8	-96	-95	-94	N/A
3/31/2017	0	-108	N/A	-101	N/A
12/31/2016	0	-112	N/A	-94	N/A
9/30/2016	N/A	-106	N/A	-86	N/A
6/30/2016	N/A	-106	N/A	-78	N/A
3/31/2016	N/A	-91	N/A	-70	N/A
12/31/2015	N/A	-71	N/A	-55	N/A
9/30/2015	4	-61	N/A	-49	N/A
6/30/2015	4	-42	N/A	-30	N/A
3/31/2015	4	-29	N/A	-18	N/A
12/31/2014	4	-20	N/A	-19	N/A
9/30/2014	0	-12	N/A	-9	N/A
6/30/2014	1	-11	N/A	-8	N/A
3/31/2014	0	-11	N/A	-8	N/A
12/31/2013	0	-11	N/A	-6	N/A
9/30/2013	1	-37	N/A	-9	N/A
6/30/2013	1	-41	N/A	-11	N/A
3/31/2013	3	-45	N/A	-10	N/A
12/31/2012	3	-50	N/A	-12	N/A
9/30/2012	4	-28	N/A	-12	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: PRTK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Ertrag vs. Markt: PRTK is forecast to become profitable over the next 3 years, which is considered above average market growth.

Hohe Wachstumserträge: PRTK is expected to become profitable in the next 3 years.

Einnahmen vs. Markt: PRTK's revenue (13.8% per year) is forecast to grow faster than the US market (7.7% per year).

Hohe Wachstumseinnahmen: PRTK's revenue (13.8% per year) is forecast to grow slower than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if PRTK's Return on Equity is forecast to be high in 3 years time

This company has been acquired

Paratek Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus estimates of losses per share improve by 16%

Forecast to breakeven in 2025

No longer forecast to breakeven

Paratek Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2023

Price target decreased by 51% to US$6.67

Forecast breakeven date pushed back to 2024

Recent updates

Paratek Pharmaceuticals, Inc. Announces Board Changes

Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from S&P Global BMI Index

CEO & Director recently sold US$108k worth of stock

Consensus estimates of losses per share improve by 16%

Forecast to breakeven in 2025

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Paratek Pharmaceuticals, Inc. Announces Modification of Barda Contract to Advance the Development of Nuzyra®? (Omadacycline) for Post-Exposure Prophylaxis (Pep) and Treatment of Pulmonary Anthrax

No longer forecast to breakeven

NexPoint Advisors Sends a Letter to Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. Presents New Data from NUZYRA®? (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023

Gurnet Point Capital Limited and Novo Holdings A/S entered into a definitive agreement to acquire Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK) for approximately $130 million.

Gurnet Point Capital Limited and Novo Holdings A/S entered into a definitive agreement to acquire Paratek Pharmaceuticals, Inc. (NasdaqGM:PRTK) for approximately $130 million.

Paratek Pharmaceuticals, Inc., Annual General Meeting, Jul 06, 2023

Paratek Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 51% to US$6.67

Improved Revenues Required Before Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Stock's 77% Jump Looks Justified

Forecast breakeven date pushed back to 2024

Consensus estimates of losses per share improve by 10%

Paratek Pharmaceuticals, Inc. Announces Inclusion of NUZYRA(R) (omadacycline) in China's National Reimbursement Drug List

Paratek Pharmaceuticals, Inc. Appoints Jeffrey Stein as First Lead Independent Director

Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA (omadacycline) under BARDA Project BioShield

CEO & Director notifies of intention to sell stock

Insufficient new directors

Consensus revenue estimates fall by 11%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Paratek Pharmaceuticals, Inc. Announces First Milestone Towards Creating A U.S. Manufacturing Supply Chain for Nuzyra® (Omadacycline) Under Barda Project Bioshield Contract

Paratek Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Paratek Pharmaceuticals: Patience Is Wearing Thin

Consensus EPS estimates fall by 33%

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Paratek Pharmaceuticals GAAP EPS of -$0.33 beats by $0.01, revenue of $29.6M beats by $0.42M

Paratek Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from Russell 2000 Dynamic Index

Consensus forecasts updated

Price target decreased to US$21.00

Forecast breakeven date pushed back to 2024

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Paratek Pharmaceuticals, Inc. Reiterates Guidance for the Year 2022

Insufficient new directors

Paratek Pharmaceuticals, Inc., Annual General Meeting, Jun 08, 2022

Consensus EPS estimates fall by 19%

Consensus revenue estimates fall by 10%

Price target decreased to US$23.00

Forecast breakeven date pushed back to 2023

Paratek Pharmaceuticals, Inc. Announces the Publication of Data from an Investigator-Initiated Study of NUZYRA in A Hollow Fiber System Model Against Pulmonary Mycobacterium Avium Complex

Paratek Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 14, 2022

Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company

President & Chief Commercial Officer notifies of intention to sell stock

Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.46 loss in 3Q 2020)

Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.46 loss in 3Q 2020)

The Play On Paratek Pharmaceuticals

Price target increased to US$25.67

Paratek Pharmaceuticals Presents New Data for NUZYRA® (omadacycline) at IDWeek 2021

Paratek Pharmaceuticals Announces FDA Orphan Drug Designation for NUZYRA (omadacycline) for the Treatment of Infections Caused by Nontuberculous Mycobacteria

Consensus EPS estimates fall to -US$1.27

Second quarter 2021 earnings released: EPS US$0.21 (vs US$0.53 loss in 2Q 2020)

Peeking Back In On Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc. Announces First Barda Project Bioshield Procurement of Nuzyra

Paratek Pharmaceuticals, Inc.(NasdaqGM:PRTK) dropped from Russell 3000E Value Index

Paratek Pharmaceuticals, Inc. Announces Initiation of Phase 2b Study in Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc) with Nuzyra (Omadacycline)

Price target decreased to US$16.00

Paratek Pharma launches Phase 2b Nuzyra study in nontuberculous mycobacterial

Paratek Pharmaceuticals Announces FDA Approval of NUZYRA® (omadacycline) Oral Only Dosing Regimen for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

Paratek shares rise after FDA approves NUZYRA oral only dosing regimen

Forecast breakeven moved forward to 2022

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.66 loss in 1Q 2020)